Anlotinib in treatment of an elderly patient with recurrent advanced SCLC
Author:
Affiliation:
1. Department of Internal Medicine, Municipal Hospital, Qingdao, Shandong, People’s Republic of China
2. Department of Medical Oncology, Municipal Hospital, Qingdao, Shandong, People’s Republic of China
Abstract
Publisher
SAGE Publications
Subject
Cancer Research,Oncology,General Medicine
Link
http://journals.sagepub.com/doi/pdf/10.1177/0300891619900673
Reference10 articles.
1. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor‐2 inhibitor
2. Small-Cell Lung Cancer: Prognostic Factors and Changing Treatment Over 15 Years
3. The International Association for the Study of Lung Cancer Lung Cancer Staging Project: Proposals for the Revision of the Clinical and Pathologic Staging of Small Cell Lung Cancer in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer
4. Unravelling the biology of SCLC: implications for therapy
5. Carboplatin- or Cisplatin-Based Chemotherapy in First-Line Treatment of Small-Cell Lung Cancer: The COCIS Meta-Analysis of Individual Patient Data
Cited by 5 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Silencing lncRNA HCG18 regulates GPX4-inhibited ferroptosis by adsorbing miR-450b-5p to avert sorafenib resistance in hepatocellular carcinoma;Human & Experimental Toxicology;2023-02-14
2. Anlotinib plus etoposide increases survival in patients with small-cell lung cancer after chemoradiotherapy;Journal of Radiation Research and Applied Sciences;2022-12
3. Safety of Anlotinib Capsules Combined with PD-1 Inhibitor Camrelizumab in the Third-Line Treatment of Advanced Non-Small-Cell Lung Cancer and Their Effect on Serum Tumor Markers;Journal of Healthcare Engineering;2021-12-15
4. Response to first‐line treatment predicts progression‐free survival benefit of small‐cell lung cancer patients treated with anlotinib;Cancer Medicine;2021-05-06
5. Antineoplastics;Reactions Weekly;2021-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3